How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,960 results for

Cholesterol Education Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial

Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention Official Title: Multicenter Randomized Trial of Structured Educational Intervention at the Community Level in Insufficiently Controlled Patients With Type 2 Diabetes in Reunion Island Actual Study Start Date : October 2011 Actual Primary Completion Date : September 2016 Actual Study Completion Date : September 2016 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go (...) Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2011 Clinical Trials

82. Culturally appropriate health education for type 2 diabetes is effective in the short-term

Culturally appropriate health education for type 2 diabetes is effective in the short-term PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View (...) education includes using community-based health advocates, delivering information within same-gender groups or adapting dietary and lifestyle advice to fit a particular community’s likely diet. Caveat None of the other clinical outcome measures, such as cholesterol, blood pressure or weight showed any improvement, nor were there any improvements in quality of life outcomes for patients. The benefits were not sustained one year later. The participants originated from developing countries but lived

2008 Cochrane PEARLS

83. Care and support of people growing older with learning disabilities

of people with learning disabilities and getting information from other support services, including education and the Department for Work and Pensions. 1.2.3 Commissioners and service providers should ensure family members, carers and advocates of people with learning disabilities have access to age-appropriate community support services and resources such as: day opportunities short respite breaks (both at home and away from home) family placements support groups for family carers, including siblings (...) health needs 18 1.6 End of life care 26 1.7 Staff skills and expertise 28 T erms used in this guideline 30 Putting this guideline into practice 33 Recommendations for research 35 1 Models of care and support at home 35 2 Identifying health conditions 35 3 Education and training programmes: self-management 36 4 Dementia education and training programmes for family members and carers 37 5 Advance planning about end of life care 37 Update information 38 Care and support of people growing older

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

84. Controlled trial of an intervention to improve cholesterol management in diabetes patients in remote Aboriginal communities. (PubMed)

Controlled trial of an intervention to improve cholesterol management in diabetes patients in remote Aboriginal communities. Aboriginal communities have a high prevalence of diabetes and heart disease, and limited resources to address them. The objective of this study was to test the effectiveness of prioritizing care with audit and feedback on cholesterol management of diabetic patients.A controlled before-after intervention trial was conducted among health care providers in Oji-Cree reserves (...) in Sioux Lookout Zone, Ontario. Two communities were randomized to receive an interactive educational workshop and chart audit with feedback on cholesterol management; 2 control communities received usual care.The primary outcome measure used was the proportion of patients on statins, and the secondary outcome measure was the proportion of patients with LDL>2.5 mmol/L or TC/HDL>4.0 on statins. Outcomes were assessed by chart review at baseline and 10 months post-intervention.Patients in the 2

2010 International journal of circumpolar health

85. Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

at Week 4 [ Time Frame: Baseline and Week 4 ] Percent Change From Baseline in Lp(a) at Week 4 [ Time Frame: Baseline and Week 4 ] Percent Change From Baseline in Apo A-I at Week 4 [ Time Frame: Baseline and Week 4 ] Percent Change From Baseline in TC at Week 4 [ Time Frame: Baseline and Week 4 ] Number of Participants Who Achieve LDL-C Target Levels at Week 12 of Treatment [ Time Frame: Baseline and 12 weeks ] assessed as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP (...) Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2010 Clinical Trials

86. Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice

room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence Other Name: Cholesterol Education and Research Trial Usual care 15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines Outcome Measures Go to Primary Outcome Measures : %patients at ATP III goals [ Time Frame: one year after intervention (...) Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2010 Clinical Trials

87. Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults

and Lower Cholesterol in Older Adults Study Start Date : October 2010 Actual Primary Completion Date : December 2013 Actual Study Completion Date : February 2014 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Medication adherence intervention Receives 12-week behavioral feedback intervention to improve adherence to statin medication Behavioral: Medication adherence intervention 12-week behavioral feedback (...) intervention to improve adherence to statin medication No Intervention: Control No intervention Active Comparator: Attention-control Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol Behavioral: Attention-control Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group Outcome Measures Go to Primary Outcome Measures : Medication adherence [ Time

2010 Clinical Trials

88. Telehealth and the use of video conferences: A Rapid Review

disease. Nor were there any reviews that focused on appointment attendance as an outcome measure. Figure 1. PRISMA flowchart of included studies Skype video conferencing 2 One review 2 looked specifically at the use of Skype, a low-cost or no-cost video conferencing tool in healthcare settings. They found that the use of Skype was most prevalent in the management of chronic diseases such as cardiovascular diseases and diabetes, followed by educational and speech and language pathology applications (...) significant reductions in HbA1c and LDL-cholesterol. These results are comparable to patient results from face-to-face visits with clinical pharmacists. There were no significant changes in the number of patients attaining their HbA1c or LDL- cholesterol goals after video conference intervention. 8 Paediatrics Patient satisfaction has been reported to be high for paediatric video conferencing, with reports of cost and time savings for patients. Patient comfort with the consultation was reported in 77

2019 Monash Health Evidence Reviews

89. Delivering novel therapies in the 21st century

antibody-drug conjugates, protein scaffolds and peptide fusions that combine functionality. These enable specificity to the drug target and bring benefits to particular disease settings. CASE STUDY 1 Antibody-peptide bispecific fusion A new antibody-peptide bispecific fusion combines different functionalities in one molecule. The monoclonal antibody a-PCSK9 lowers low density lipoprotein (so-called ‘bad’ cholesterol) in patients with cardiovascular disease. When bound to the peptide GLP-1R, which (...) the liver to restore function: while AAV alone repairs only 0.4% of cells, using AAV and CRISPR-Cas9 together repairs 6% of the liver. Fully synthetic systems are now being developed that do not require viruses for in vivo genome editing, by chemically modifying guide mRNA. This is being applied to create a single-administration treatment to lower cholesterol by deactivating the gene PCSK9. “I think that nanoparticles will be key to deliver genome editing tools, making drugs that repair your DNA while

2019 Academy of Medical Sciences

90. Productive healthy ageing: interventions for quality of life

for Productive Healthy Ageing 5 changing them, if appropriate) or by encouraging older people to increase their physical activity, reduce alcohol intake, maintain a healthy weight and balanced diet. The Centre for Pharmacy Postgraduate Education (CPPE), funded by Health Education England (HEE), provides a range of e-learning resources on topics such as Dementia and Older people. Pharmacy staff may want to use these learning materials to better support older people to live healthier lives to support (...) isolation and loneliness 16 Malnutrition 18 Improving public mental health 21 Further information, tools and resources 23 References 25 A Menu of Interventions for Productive Healthy Ageing 4 Introduction The Menu of Interventions (MOIs) for productive health ageing is a guide that pharmacy teams working in different healthcare settings can use to support older people to improve the quality of their lives. It suggests opportunistic, evidence-based interventions that can help provide benefits for healthy

2019 Public Health England

91. Oral care and people with learning disabilities

people. This might include making practical adjustments to the environment or changes in the process. This guidance signposts resources that can be used to support people with learning disabilities with their oral care. There are strategies that can be used to help reduce anxiety and better prepare people for dental treatment, such as desensitisation. There is a need for training and education for people with learning disabilities, their family carers and supporters and dental professionals (...) (an update from one on the same topic published in 2012) is one in a looking at reasonable adjustments in a specific service area. The aim is to share information, ideas and good practice in relation to the provision of reasonable adjustments. We searched for policy, guidelines, research and resources that relate to people with learning disabilities and oral care and dental services. We put a request out through a range of networks for people interested in services and care for people with learning

2019 Public Health England

92. Guidelines on Chronic Coronary Syndromes

IMT Intima−media thickness IONA Impact Of Nicorandil in Angina iwFR Instantaneous wave-free ratio (instant flow reserve) LAD Left anterior descending LBBB Left bundle branch block LDL-C Low-density lipoprotein cholesterol LM Left main (coronary artery) LV Left ventricular LVEF Left ventricular ejection fraction MI Myocardial infarction MRA Mineralocorticoid receptor antagonist NOAC Non-vitamin K antagonist oral anticoagulant NT-proBNP N-terminal pro-B-type natriuretic peptide OAC Oral (...) on the ESC website ( ). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. The ESC carries out a number of registries which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on data collected during routine clinical practice. The guidelines are developed together with derivative

Full Text available with Trip Pro

2019 European Society of Cardiology

93. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD

are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on data collected during routine clinical practice. The guidelines are developed together with derivative educational material addressing the cultural and professional needs for cardiologists and allied professionals. Collecting high-quality observational data, at appropriate time interval (...) disease HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly HbA1c Haemoglobin A1c HEART2D Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus HDL-C High-density lipoprotein cholesterol HF Heart failure HFmrEF Heart failure with mid-range ejection fraction HFpEF Heart failure with preserved

Full Text available with Trip Pro

2019 European Society of Cardiology

94. National Adult Diabetes Clinician Guide

depending on baseline HbA1C, baseline BMI (> 30 vs. 9 lbs., a diagnosis of GDM or polycystic ovary syndrome (PCOS) ? hypertension (= 140/90 mmHg or on therapy for hypertension) ? high-density lipoprotein cholesterol (HDL-C) level 250 mg/dl (2.82 mmol/l), or both ? HbA1c = 5.7%, IGT, or IFG on previous testing ? other clinical conditions associated with insulin resistance (e.g., severe obesity [defined as BMI = 40 kp/m 2 ], acanthosis nigricans) CLINICAL PRACTICE GUIDELINES | NATL February 2019 BLOOD (...) • Simultaneous use of an ACEI, ARB, and/or renin inhibitor is potentially harmful and is not recommended. • Do not prescribe ACEIs/ARBs, to women of childbearing potential, unless there is a compelling indication. Additional Details CLINICAL PRACTICE GUIDELINES | NATL February 2019 • For additional details, see KP Blood Pressure guideline. CHOLESTEROL THERAPY • See Cholesterol and Cardiovascular Risk guideline. ASPIRIN THERAPY • See Integrated Cardiovascular Health Clinical Leads interim guidance on aspirin

2019 Kaiser Permanente National Guideline Program

95. Management of Dyslipidaemias

and are regularly updated. The ESC carries out a number of registries which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on data collected during routine clinical practice. The guidelines are developed together with derivative educational material addressing the cultural and professional needs for cardiologists and allied professionals (...) and lipoproteins in the pathophysiology of atherosclerosis 17 5.3 Evidence for the causal effects of lipids and lipoproteins on the risk of atherosclerotic cardiovascular disease 18 5.3.1 Low-density lipoprotein cholesterol and risk of atherosclerosis 18 5.3.2 Triglyceride-rich lipoproteins and risk of atherosclerosis 18 5.3.3 High-density lipoprotein cholesterol and risk of atherosclerosis 19 5.3.4 Lipoprotein(a) and risk of atherosclerosis 19 5.4 Laboratory measurement of lipids and lipoproteins 19 5.4.1

Full Text available with Trip Pro

2019 European Society of Cardiology

96. Public health service provision by community pharmacies: a systematic map of evidence

; Fajemisin 2013) and might be a person's only point of contact with a healthcare professional (LGA 2013). The range of services provided in community pharmacies are broad and varied, ranging from long- established services such as prescription services and sale of over the counter medicines, to health advice, education, distribution and advice around emergency hormonal contraception (EHC) and condoms and information or testing for specific conditions such as cholesterol testing. Further services (...) : This report should be cited as: Stokes G, Rees R, Khatwa M, Stansfield C, Burchett H, Dickson, K, Brunton G, Thomas J (2019) Public health service provision by community pharmacies: a systematic map of evidence. London: EPPI-Centre, Social Science Research Unit, Institute of Education, University College London. Funding This report is independent research commissioned by the National Institute for Health Research (NIHR) Policy Research Programme (PRP) for the Department of Health and Social Care (DHSC

2019 EPPI Centre

97. Management of stable angina

Perioperative revascularisation 33 6.3 Drug therapy in patients undergoing non-cardiac surgery 34 7 Psychological health 38 7.1 How does angina affect quality of life? 38 7.2 Improving symptom control with behavioural interventions 39 7.3 The effect of health beliefs on symptoms and functional status 40 8 Provision of information 41 8.1 Information and education about surgery and other interventions 41 8.2 Cardiac waiting times 42 8.3 Follow up in patients with angina 42 8.4 Checklist for provision (...) of information 43 8.5 Publications from SIGN 44 Management of stable angina Contents8.6 Sources of further information 44 9 Implementing the guideline 46 9.1 Implementation strategy 46 9.2 Resource implications of key recommendations 46 9.3 Auditing current practice 46 9.4 Health technology assessment advice for NHSScotland 47 10 The evidence base 48 10.1 Systematic literature review 48 10.2 Recommendations for research 48 10.3 Review and updating 49 11 Development of the guideline 50 11.1 Introduction 50

2018 SIGN

98. Canadian stroke best practice recommendations: secondary prevention of stroke, sixth edition practice guidelines

, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new rec- ommendations regarding the management of patent foramen ovale, and the removal of the recommendations on man- agement of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources (...) , and those who are hospitalized because of stroke or transient ischemic attack. Each section of these recommendations is supported by detailedevidencetablesandasummaryoftheevidence, a rationale for the importance of the topic, system implications to facilitate timely and e?cient implemen- tation, key quality indicators for measuring perform- ance and resources to support implementation and uptake for health care professionals and for patients. These are available at www.strokebestpractices.ca. Section 1

2018 CPG Infobase

99. Assessment of elevated creatinine

creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006 Jan;52(1):5-18. http://www.clinchem.org/cgi/content/full/52/1/5 http://www.ncbi.nlm.nih.gov/pubmed/16332993?tool=bestpractice.com Combining HPLC with IDMS provides highly accurate results, but is not available in most centres. POCT-based serum creatinine measurement appears to be sufficiently accurate for clinical use. Calzavacca P, Tee A, Licari E, et al. Point-of-care (...) with the Jaffe method by 20% or more in conditions such as diabetic ketoacidosis. The non-creatinine chromogens do not significantly affect urine creatinine levels, and have a smaller effect on the total reaction in advanced renal dysfunction than in normal renal function. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006 Jan;52(1):5-18. http

2018 BMJ Best Practice

100. Assessment of elevated creatinine

creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006 Jan;52(1):5-18. http://www.clinchem.org/cgi/content/full/52/1/5 http://www.ncbi.nlm.nih.gov/pubmed/16332993?tool=bestpractice.com Combining HPLC with IDMS provides highly accurate results, but is not available in most centres. POCT-based serum creatinine measurement appears to be sufficiently accurate for clinical use. Calzavacca P, Tee A, Licari E, et al. Point-of-care (...) with the Jaffe method by 20% or more in conditions such as diabetic ketoacidosis. The non-creatinine chromogens do not significantly affect urine creatinine levels, and have a smaller effect on the total reaction in advanced renal dysfunction than in normal renal function. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006 Jan;52(1):5-18. http

2018 BMJ Best Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>